| |
| |
|
| Insider
Information: |
Lyons Gary A |
| Relationship: |
|
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
506,803 |
|
|
Indirect Shares
|
387,931 |
|
|
| Direct
Value |
$17,047,060 |
|
|
|
Indirect Value
|
$53,482,716 |
|
|
| Total
Shares |
894,734 |
|
|
| Total
Value |
$70,529,776 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Neurocrine Biosciences Inc |
NBIX |
Director |
2024-05-17 |
119,047 |
2005-12-19 |
383,573 |
Premium* |
|
|
Ardea Biosciences Inc |
RDEA |
Director |
2003-11-25 |
0 |
2003-11-25 |
0 |
Premium* |
|
|
Fresh Tracks Therapeutics Ord Shs |
FRTX |
Director |
2020-12-31 |
18,762 |
2009-05-21 |
0 |
Premium* |
|
|
Poniard Pharmaceuticals |
PARD |
Director |
2011-07-11 |
206,145 |
2010-07-12 |
0 |
Premium* |
|
|
Plus Therapeutics Inc |
PSTV |
Director |
2015-05-08 |
36,849 |
2016-06-15 |
4,358 |
Premium* |
|
|
Travere Therapeutics, Inc |
TVTX |
|
2024-05-08 |
51,000 |
2014-10-08 |
0 |
Premium* |
|
|
Rigel Pharmaceuticals Inc |
RIGL |
|
2023-05-26 |
75,000 |
2021-05-19 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
114 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 4 of 5
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| PARD |
Poniard Pharmaceuticals |
Director |
– • – |
2011-06-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
36,145 |
121,145 |
0 |
- |
|
| PARD |
Poniard Pharmaceuticals |
Director |
– • – |
2011-07-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
85,000 |
206,145 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2014-03-07 |
4 |
OE |
$10.98 |
$933,300 |
D/D |
85,000 |
357,495 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2015-01-20 |
4 |
OE |
$4.76 |
$35,700 |
D/D |
7,500 |
291,664 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2015-02-10 |
4 |
OE |
$4.76 |
$35,700 |
D/D |
7,500 |
298,062 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2016-05-06 |
4 |
OE |
$3.07 |
$46,050 |
D/D |
15,000 |
267,066 |
0 |
- |
|
| PSTV |
Plus Therapeutics Inc |
Director |
– • – |
2016-06-15 |
4 |
OE |
$0.00 |
$0 |
I/I |
1,900 |
4,358 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2017-02-14 |
4 |
OE |
$3.40 |
$51,000 |
D/D |
15,000 |
282,066 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2018-04-03 |
4 |
OE |
$7.05 |
$105,750 |
D/D |
15,000 |
277,066 |
0 |
- |
|
| FRTX |
Fresh Tracks Therapeutics... |
Director |
– • – |
2020-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,491 |
3,491 |
0 |
- |
|
| FRTX |
Fresh Tracks Therapeutics... |
Director |
– • – |
2020-02-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
692 |
2,437 |
0 |
- |
|
| FRTX |
Fresh Tracks Therapeutics... |
Director |
– • – |
2020-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
691 |
2,782 |
0 |
- |
|
| FRTX |
Fresh Tracks Therapeutics... |
Director |
– • – |
2020-04-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
692 |
3,128 |
0 |
- |
|
| FRTX |
Fresh Tracks Therapeutics... |
Director |
– • – |
2020-05-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
692 |
3,474 |
0 |
- |
|
| FRTX |
Fresh Tracks Therapeutics... |
Director |
– • – |
2020-06-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
691 |
21,080 |
0 |
- |
|
| FRTX |
Fresh Tracks Therapeutics... |
Director |
– • – |
2020-07-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
692 |
21,426 |
0 |
- |
|
| FRTX |
Fresh Tracks Therapeutics... |
Director |
– • – |
2020-08-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
692 |
21,772 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2022-04-25 |
4 |
OE |
$6.66 |
$99,900 |
D/D |
15,000 |
223,697 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2022-10-31 |
4 |
OE |
$12.71 |
$190,650 |
D/D |
15,000 |
218,697 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2023-09-01 |
4 |
OE |
$12.98 |
$64,900 |
D/D |
5,000 |
208,697 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2023-09-12 |
4 |
OE |
$12.98 |
$64,900 |
D/D |
5,000 |
208,697 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2023-12-01 |
4 |
OE |
$12.98 |
$64,900 |
D/D |
5,000 |
208,697 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2024-05-14 |
4 |
OE |
$42.76 |
$534,500 |
D/D |
12,500 |
129,447 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2024-05-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,100 |
119,047 |
0 |
- |
|
| RDEA |
Ardea Biosciences Inc |
Director |
– • – |
2003-11-25 |
4 |
S |
$13.74 |
$1,140 |
D/D |
(83) |
0 |
|
- |
|
114 Records found
|
|
Page 4 of 5 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
